Global Retirement Partners LLC Acquires 6,570 Shares of Abbott Laboratories $ABT

Global Retirement Partners LLC raised its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 14.6% in the third quarter, Holdings Channel reports. The fund owned 51,718 shares of the healthcare product maker’s stock after acquiring an additional 6,570 shares during the period. Global Retirement Partners LLC’s holdings in Abbott Laboratories were worth $5,111,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Farther Finance Advisors LLC grew its stake in Abbott Laboratories by 14.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 84,377 shares of the healthcare product maker’s stock worth $8,339,000 after buying an additional 10,431 shares during the last quarter. Juncture Wealth Strategies LLC bought a new position in shares of Abbott Laboratories in the third quarter valued at $658,000. Aureus Asset Management LLC boosted its position in shares of Abbott Laboratories by 25.0% in the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock valued at $34,078,000 after purchasing an additional 66,422 shares during the period. Thompson Investment Management Inc. increased its position in shares of Abbott Laboratories by 786.0% in the second quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock worth $1,276,000 after acquiring an additional 12,474 shares in the last quarter. Finally, Clear Harbor Asset Management LLC purchased a new stake in shares of Abbott Laboratories in the second quarter valued at $4,889,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Down 0.2%

Shares of Abbott Laboratories stock opened at $104.48 on Thursday. The business has a fifty day simple moving average of $103.88 and a 200 day simple moving average of $101.71. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $131.49. The stock has a market cap of $180.96 billion, a PE ratio of 38.99, a price-to-earnings-growth ratio of 1.84 and a beta of 0.54. The company has a quick ratio of 1.00, a current ratio of 1.45 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting the consensus estimate of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The firm had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same quarter in the prior year, the firm earned $1.30 earnings per share. The business’s quarterly revenue was up 14.5% on a year-over-year basis. Research analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, November 16th. Shareholders of record on Thursday, October 15th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is 94.03%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ABT shares. Barclays assumed coverage on shares of Abbott Laboratories in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 target price for the company. JPMorgan Chase & Co. cut their price objective on Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, October 22nd. Royal Bank Of Canada dropped their price objective on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday, October 22nd. Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a research note on Thursday, August 13th. Finally, BTIG Research reduced their target price on shares of Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $118.32.

View Our Latest Stock Report on ABT

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total value of $406,000.00. Following the sale, the executive vice president owned 100,791 shares in the company, valued at approximately $11,691,756. The trade was a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Read More

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.